CA2853779C - Combined therapy with interferon and andrographolides for multiple sclerosis - Google Patents

Combined therapy with interferon and andrographolides for multiple sclerosis Download PDF

Info

Publication number
CA2853779C
CA2853779C CA2853779A CA2853779A CA2853779C CA 2853779 C CA2853779 C CA 2853779C CA 2853779 A CA2853779 A CA 2853779A CA 2853779 A CA2853779 A CA 2853779A CA 2853779 C CA2853779 C CA 2853779C
Authority
CA
Canada
Prior art keywords
group
formula
andrographolide
interferon beta
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2853779A
Other languages
English (en)
French (fr)
Other versions
CA2853779A1 (en
Inventor
Juan L. Hancke Orozco
Rafael Burgos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INNOBIOSCIENCE LLC
Original Assignee
INNOBIOSCIENCE LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2853779(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by INNOBIOSCIENCE LLC filed Critical INNOBIOSCIENCE LLC
Publication of CA2853779A1 publication Critical patent/CA2853779A1/en
Application granted granted Critical
Publication of CA2853779C publication Critical patent/CA2853779C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2853779A 2011-12-21 2012-12-19 Combined therapy with interferon and andrographolides for multiple sclerosis Active CA2853779C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578650P 2011-12-21 2011-12-21
US61/578,650 2011-12-21
PCT/US2012/070568 WO2013096423A1 (en) 2011-12-21 2012-12-19 Combination therapy with interferon and andrographolides for multiple sclerosis

Publications (2)

Publication Number Publication Date
CA2853779A1 CA2853779A1 (en) 2013-06-27
CA2853779C true CA2853779C (en) 2016-04-26

Family

ID=48669439

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2853779A Active CA2853779C (en) 2011-12-21 2012-12-19 Combined therapy with interferon and andrographolides for multiple sclerosis

Country Status (10)

Country Link
US (1) US9060994B2 (https=)
EP (1) EP2670406B1 (https=)
JP (1) JP5936707B2 (https=)
AU (1) AU2012359081B2 (https=)
BR (1) BR112014015178A2 (https=)
CA (1) CA2853779C (https=)
CL (1) CL2014001663A1 (https=)
ES (1) ES2554459T3 (https=)
RU (1) RU2014113967A (https=)
WO (1) WO2013096423A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3468553T3 (da) * 2016-06-08 2023-07-03 Innobioscience Llc Andrographolid behandler progressive former for multipel sklerose
US11318153B2 (en) 2018-06-25 2022-05-03 Bialpha International Sdn. Bhd. Method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function
CN109824655B (zh) * 2019-04-08 2021-09-24 沈阳药科大学 穿心莲内酯化合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043027A1 (en) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Treatment of multiple sclerosis with a combination of Interferon and Growth hormone
US6410590B1 (en) * 2000-02-03 2002-06-25 Dr. Reddy's Research Foundation Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
US20050181033A1 (en) 2000-06-29 2005-08-18 Dekker John P.Iii Method for delivering interferons to the intradermal compartment
AU2002326991A1 (en) * 2001-09-18 2003-04-01 Chiron Corporation Methods for treating multiple sclerosis
MXPA06008738A (es) * 2004-02-03 2008-03-07 Univ Austral De Chile Composicion que comprende una mezcla de lavadnos diterpenicos, de un extracto de planta andrographis paniculata, seleccionado de andrografolido, 14-deoxiandrografolido y neoandrografolido; sus usos.
US20050220764A1 (en) * 2004-04-01 2005-10-06 Schering Aktiengesellschaft Higher-doses of interferon-beta for treatment of multiple sclerosis
US20080108641A1 (en) 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법

Also Published As

Publication number Publication date
RU2014113967A (ru) 2016-02-10
ES2554459T3 (es) 2015-12-21
CL2014001663A1 (es) 2015-02-27
WO2013096423A1 (en) 2013-06-27
AU2012359081A1 (en) 2014-06-05
EP2670406B1 (en) 2015-09-02
NZ625051A (en) 2016-07-29
JP2015500880A (ja) 2015-01-08
AU2012359081B2 (en) 2015-09-17
US9060994B2 (en) 2015-06-23
JP5936707B2 (ja) 2016-06-22
US20140301981A1 (en) 2014-10-09
EP2670406A4 (en) 2014-05-28
BR112014015178A2 (pt) 2017-06-13
EP2670406A1 (en) 2013-12-11
CA2853779A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
Brück et al. Insight into the mechanism of laquinimod action
US20120328566A9 (en) Estrogen receptor ligand treatment for neurodegenerative diseases
US20210137943A1 (en) Estrogen combination for treatment of multiple sclerosis
JP6290962B2 (ja) 多発性硬化症を治療するためのクラドリビン投薬計画
Guo et al. Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis
CA2853779C (en) Combined therapy with interferon and andrographolides for multiple sclerosis
AU2017347838A1 (en) Composition comprising an anti-Αβ protofibril antibody and a beta-secretase BACE1 inhibitor for the treatment of Alzheimer's disease
US20130202555A1 (en) Treatment of multiple sclerosis with masitinib
JP2021165304A (ja) アンドログラホリドが進化型の多発性硬化症を処置する
NZ625051B2 (en) Combination therapy with interferon and andrographolides for multiple sclerosis
US20220193030A1 (en) Use of ginkgo terpene lactone in preparing drug for preventing and/or treating guillain-barre-strohl syndrome
RU2805061C2 (ru) Лечение демиелинизирующих заболеваний
US8664209B2 (en) Daptomycin for multiple sclerosis
RU2786476C2 (ru) Композиция, содержащая антитело против протофибрилл абета и ингибитор бета-секретазы васе1 для лечения болезни альцгеймера
AU2010308364A1 (en) Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140408

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240828

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240828

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240828

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251024